Sexual Wellness

Palatin Technologies Partners with UpScriptHealth to Ease Access to HSDD Treatment Vyleesi

Palatin Technologies has announced a partnership with telehealth service provider UpScriptHealth. The collaboration aims to raise awareness about hypoactive sexual desire disorder (HSDD) and increase the accessibility of Vyleesi through UpScriptHealth’s Women’s Health Platform. According to the company Vyleesi is the only FDA-approved, as-needed treatment for acquired, generalized HSDD in premenopausal women. The partnership will make Vyleesi available to UpScriptHealth’s extensive patient…

New Report by Reproductive Health Platform Rescripted Unveils Troubling State of Sex Education in 2023

Rescripted‘s “State of Sex Ed in 2023” report exposes alarming realities about sex education in the digital age. Despite relying on social media for information, 76% of individuals distrust it as a source of misinformation. Moreover, the survey of 1,000 Rescripted community members highlights a lack of self-awareness, with only 29% feeling like experts on their own bodies. Inadequate Knowledge The report…

From Sexologist to Startup Founder: How Rebecca Alvarez Story’s Pioneering Work Helped Create the Sexual Wellness Category

Five years ago in a rapidly evolving world, where conversations about intimacy were often hushed and products remained hidden in the shadows, sexologist Rebecca Alvarez Story, set out on a remarkable mission. With years of experience supporting individuals on their journeys towards sexual wellness, she recognized the need for a paradigm shift in the space and created Bloomi, a category-defining brand that…

Center for Intimacy Justice and US Senators Call on FTC to Investigate Meta’s Rejection of Women’s Sexual Health Ads

The Center for Intimacy Justice (CIJ) has filed a complaint with the Federal Trade Commission (FTC) requesting that the FTC take action regarding Meta’s systemic rejections of women’s health information and advertisements. Today, a number of Congressmembers — led by Senators Elizabeth Warren, Amy Klobuchar, Mazie Hirono, Peter Welch, and Representative Adam Schiff — published a public letter to the FTC asking…

Midnight Health, Australia’s Same-day Abortion Pill Delivery Pioneer, Adds $24M in Series B Funding

Australian remote healthcare company Midnight Health has raised $24M in Series B funding leb by nib, an insurer and strategic investor, bringing the company’s total funding since inception in 2021 to $40M. The capital injection will support Midnight Health’s growth throughout Australia, will boost IT infrastructure, and help the company refine its service platforms. Nic Blair, Midnight Health’s CEO, comments: “We’re really…

Futura Medical Raises £4.37M After Winning FDA Approval for Its ED Topical Gel

In a breakthrough development for men’s sexual health, the US Food and Drug Administration (FDA) has granted over-the-counter (OTC) marketing authorization to Futura Medical’s topical gel, MED3000, a first-of-its-kind treatment for erectile dysfunction (ED). The quick-acting gel formulation, delivered through Futura’s proprietary DermaSys drug delivery technology, starts working within 10 minutes of application, promising an innovative solution for millions of men globally.…

Daré Bioscience Reports Positive Results for Its Sildenafil Cream in Women with Sexual Arousal Disorder

Daré Bioscience, in collaboration with Strategic Science & Technologies, has announced positive topline data from a Phase 2b study evaluating Sildenafil Cream as a treatment for female sexual arousal disorder (FSAD). The study showed meaningful improvement in the Arousal-Sensation Domain of the Sexual Function Questionnaire for patients treated with Sildenafil Cream. Additionally, improvements were observed in secondary and exploratory endpoints related to…

Gedea Biotech Secures €1.3M to Accelerate the Market Launch of Its Antibiotic-Free Vaginal Infection Treatment

Swedish women’s health company Gedea Biotech has raises €1.3M (14 MSEK) to further develop its pHyph, an innovative antibiotic-free treatment for vaginal infections. Vaginal infections affect over 400 million women annually. The fresh funds will support critical development activities, including ongoing proof-of-concept studies, clinical trials, and exploring the impact of pHyph on the vaginal microbiome. The funding round attracted current and new…